Treatment paradigms for the newly diagnosed patient with multiple myeloma.
The management of newly diagnosed multiple myeloma is currently being revolutionized by the emergence of novel therapeutic agents. Thalidomide, the thalidomide analogue lenalidomide, and the proteasome inhibitor bortezomib each have potential roles to play in the initial therapy of myeloma that are supported by encouraging clinical trials results. While evaluation for stem cell transplantation (SCT) remains a part of the algorithm for management of the newly diagnosed patient, these drugs offer improved options for induction before, and possibly maintenance after, SCT. For the patient who is not a candidate for SCT the armamentarium for management has been significantly expanded. This review will summarize currently available data regarding these exciting agents and will describe therapeutic strategies currently on the horizon.
Greipp
Philip
P
Hematologic Malignancies Program, The Mayo Clinic, Rochester, MN 55905, USA. greipp@mayo.edu
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001897:Boronic Acids / Q000627:therapeutic use*; D000069286:Bortezomib; D003907:Dexamethasone / Q000627:therapeutic use*; D006801:Humans; D000077269:Lenalidomide; D009101:Multiple Myeloma / Q000175:diagnosis* / Q000188:drug therapy*; D011719:Pyrazines / Q000627:therapeutic use*; D033581:Stem Cell Transplantation; D013792:Thalidomide / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D001897:Boronic Acids; D011719:Pyrazines; D013792:Thalidomide; D000069286:Bortezomib; D003907:Dexamethasone; D000077269:Lenalidomide